Integrated Three Japanese Institution's Experience of Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma Treated with Yittrium 90 Ibritumomab Tiuxetan (Zevalin): Factors Associated with Long-Term Responses

Integrated Three Japanese Institution's Experience of Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma Treated with Yittrium 90 Ibritumomab Tiuxetan (Zevalin): Factors Associated with Long-Term Responses - J3Zi Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037105

Enrollment

320

Registered

2019-06-19

Start date

2019-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-Cell Non-Hodgkin Lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Neutrophil count >= 1.2x109/L 2 Platelet count >= 100x109/L 3 Bone marrow infiltration rate < 25% 4 Zevalin treatment date before 2018/5/31 (in attempt to be more than one year of follow-up )

Exclusion criteria

Exclusion criteria: 1 No efficacy evaluation of Zevalin treatmen using PET or CT 2 No follow-up after Zevalin treatment

Design outcomes

Primary

Measure	Time frame
1) Progression-free survival (PFS)median time after Zevalin treatment 2) Overall survival (OS)meedian time after Zevalin treatment 3) Two years PFS after Zevalin treatment 4) Five years OS after Zevalin treatment	—

Secondary

Measure	Time frame
Efficacy: 1) Five years PFS after Zevalin treatment 2) One year PFS after Zevalin treatment 3) Two years OS after Zevalin treatment 4) One year OS after Zevalin treatment Safety: 1) Occurrence rate of hematological toxicity grade >=3 within 12 weeks after Zevalin treatment 2) Occurrence rate of hematological toxicity grade >=4 within 12 weeks after Zevalin treatment 3) With or without hematological treatment (platelet blood transfusion, red blood cell transfusion, C-GSF treatment) within 12 weeks after Zevalin treatment 4) With or without infection disease treatment within one year after Zevalin treatment 5) Occurrence rate of subsequent neoplasms (t-MDS/AML) in patient follow-up more than 2 years	—

Measure

Time frame

Efficacy: 1) Five years PFS after Zevalin treatment 2) One year PFS after Zevalin treatment 3) Two years OS after Zevalin treatment 4) One year OS after Zevalin treatment Safety: 1) Occurrence rate of hematological toxicity grade >=3 within 12 weeks after Zevalin treatment 2) Occurrence rate of hematological toxicity grade >=4 within 12 weeks after Zevalin treatment 3) With or without hematological treatment (platelet blood transfusion, red blood cell transfusion, C-GSF treatment) within 12 weeks after Zevalin treatment 4) With or without infection disease treatment within one year after Zevalin treatment 5) Occurrence rate of subsequent neoplasms (t-MDS/AML) in patient follow-up more than 2 years

—

Countries

Japan

Contacts

Public ContactTakehisa Yamamoto

Sagano Co., Ltd. Science Support Planning Division

takehisa.yamamoto@saganocorp.jp0353387654

Outcome results